Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03932318 | Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients | withdrawn | Phase 1 / Phase 2 | 0 | Actinium PharmaceuticalsINDUSTRY | 0 | Jul 20, 2023 | clinicaltrials |
| NCT05171062 | Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT05109052 | Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | University of RochesterOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05191004 | Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | withdrawn | Phase 1 / Phase 2 | 0 | Nuvation Bio Inc.INDUSTRY | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05604417 | Zandelisib + Tazemetostat in R/R Follicular Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Jacob Soumerai, MDOTHER | 0 | Jul 7, 2023 | clinicaltrials |
| NCT05934097 | FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | withdrawn | Phase 1 | 0 | Fate TherapeuticsINDUSTRY | 0 | Jul 6, 2023 | clinicaltrials |
| NCT03552796 | sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer | withdrawn | Phase 1 | 0 | University of Southern CaliforniaOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT05063357 | 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma | withdrawn | Phase 1 | 0 | Y-mAbs TherapeuticsINDUSTRY | 0 | Jun 26, 2023 | clinicaltrials |
| NCT04896320 | Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.(2019-101826) | withdrawn | Phase 1 / Phase 2 | 0 | Providence Health & ServicesOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05037669 | Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma | withdrawn | Phase 1 | 0 | University of PennsylvaniaOTHER | 0 | Jun 22, 2023 | clinicaltrials |
| NCT04896112 | A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Lynk Pharmaceuticals Co., LtdINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05431582 | Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jun 15, 2023 | clinicaltrials |
| NCT05152459 | Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | City of Hope Medical CenterOTHER | 0 | May 31, 2023 | clinicaltrials |
| NCT02344810 | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 1 | May 25, 2023 | clinicaltrials |
| NCT05774886 | Implantable Microdevice for TNBC - Pilot Study | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | May 18, 2023 | clinicaltrials |
| NCT04741984 | Monocyte Antigen Carrier Cells for Newly Diagnosed GBM(DEMAND) | withdrawn | Phase 1 | 0 | Michael GunnOTHER | 0 | May 15, 2023 | clinicaltrials |
| NCT05251038 | Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Devalingam MahalingamOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT04872608 | A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer | withdrawn | Phase 1 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT04879589 | Phase 1 Study of ATRS-2002 in Healthy Male Adults | withdrawn | Phase 1 | 0 | Syneos HealthOTHER | 0 | Apr 28, 2023 | clinicaltrials |
| NCT01971489 | Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05330377 | GM-CLAG in Relapsed/Refractory FLT3-mutated AML | withdrawn | Phase 1 | 0 | Ayman H QasrawiOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT05220748 | RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC | withdrawn | Phase 1 | 0 | Rakuten Medical, Inc.INDUSTRY | 0 | Apr 19, 2023 | clinicaltrials |
| NCT04852367 | PanDox: Targeted Doxorubicin in Pancreatic Tumours(PanDox) | withdrawn | Phase 1 | 0 | University of OxfordOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT01332279 | Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy | withdrawn | Phase 1 | 0 | Fox Chase Cancer CenterOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT03121989 | Study to Evaluate the Feasibility of 13-C Pyruvate Imaging in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy(LABC) | withdrawn | Phase 1 | 0 | Sunnybrook Health Sciences CentreOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT05365100 | A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL | withdrawn | Phase 1 / Phase 2 | 0 | BioNova Pharmaceuticals (Shanghai) LTD.INDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01316146 | Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30) | withdrawn | Phase 1 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT04252768 | A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel(AIPAC-002) | withdrawn | Phase 1 | 0 | Immutep S.A.S.INDUSTRY | 0 | Mar 22, 2023 | clinicaltrials |
| NCT04826016 | POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer(POLTER) | withdrawn | Phase 1 / Phase 2 | 0 | MedSIROTHER | 0 | Mar 20, 2023 | clinicaltrials |
| NCT05259397 | PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) | withdrawn | Phase 1 | 0 | PfizerINDUSTRY | 2 | Mar 8, 2023 | clinicaltrials |
| NCT05693090 | Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | Kura Oncology, Inc.INDUSTRY | 1 | Mar 6, 2023 | clinicaltrials |
| NCT05513612 | Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies | withdrawn | Phase 1 | 0 | Shanghai Pudong HospitalOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT05222165 | Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations(NEWEL) | withdrawn | Phase 1 / Phase 2 | 0 | Helsinn Healthcare SAINDUSTRY | 3 | Feb 23, 2023 | clinicaltrials |
| NCT04759846 | Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma | withdrawn | Phase 1 | 0 | Pierre Fabre MedicamentINDUSTRY | 3 | Feb 21, 2023 | clinicaltrials |
| NCT04868045 | Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer | withdrawn | Phase 1 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Feb 21, 2023 | clinicaltrials |
| NCT05176691 | HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL | withdrawn | Phase 1 | 0 | HutchmedINDUSTRY | 7 | Feb 21, 2023 | clinicaltrials |
| NCT04877080 | CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHL | withdrawn | Phase 1 | 0 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 0 | Feb 10, 2023 | clinicaltrials |
| NCT03338881 | A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies | withdrawn | Phase 1 | 0 | Calithera Biosciences, IncINDUSTRY | 0 | Feb 8, 2023 | clinicaltrials |
| NCT03359733 | A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor | withdrawn | Phase 1 | 0 | Calithera Biosciences, IncINDUSTRY | 1 | Feb 8, 2023 | clinicaltrials |
| NCT03772288 | A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL) | withdrawn | Phase 1 | 0 | Calithera Biosciences, IncINDUSTRY | 2 | Feb 8, 2023 | clinicaltrials |
| NCT05381935 | A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors | withdrawn | Phase 1 | 0 | Elpiscience Biopharma, Ltd.INDUSTRY | 0 | Jan 31, 2023 | clinicaltrials |
| NCT05408026 | Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM | withdrawn | Phase 1 / Phase 2 | 0 | Alliance Foundation Trials, LLC.OTHER | 0 | Jan 27, 2023 | clinicaltrials |
| NCT05493618 | Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma. | withdrawn | Phase 1 / Phase 2 | 0 | Hackensack Meridian HealthOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT02389543 | Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients(SLAM) | withdrawn | Phase 1 / Phase 2 | 0 | Karyopharm Therapeutics IncINDUSTRY | 0 | Jan 26, 2023 | clinicaltrials |
| NCT05060276 | Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors | withdrawn | Phase 1 | 0 | Sorrento Therapeutics, Inc.INDUSTRY | 0 | Jan 26, 2023 | clinicaltrials |
| NCT05628545 | Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells | withdrawn | Phase 1 / Phase 2 | 0 | Guangdong GD Kongming Biotech LLCINDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT04797468 | A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor | withdrawn | Phase 1 | 0 | Shanghai Henlius BiotechINDUSTRY | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05228249 | Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT00995059 | Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | Mayo ClinicOTHER | 0 | Jan 5, 2023 | clinicaltrials |
| NCT05472220 | Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma | withdrawn | Phase 1 | 0 | Pamela MunsterOTHER | 0 | Dec 27, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jul 20, 2023source: clinicaltrials